Grace Therapeutics (GRCE) announced details of the Company’s Type C meeting with the U.S. Food and Drug Administration. The purpose of this meeting was to obtain FDA feedback on the completed Phase 3 STRIVE-ON safety trial of GTx-104 and its planned New Drug Application submission including clinical, non-clinical, and chemistry, manufacturing, and control requirements. Based on feedback from the FDA, the Company believes that the data and regulatory packages as currently structured will be sufficient for submission of an NDA.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GRCE:
- Grace Therapeutics Reports Q3 Progress and Financial Results
- Grace Therapeutics Files Form S-3 for Flexible Securities Offering
- Grace Therapeutics files to sell 8.84M shares of common stock for holders
- Promising Potential of Grace Therapeutics’ GTX-104 Drives Buy Rating
- Grace Therapeutics reports Q3 EPS (36c), consensus (46c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue